Perillyl alcohol for the treatment of temozolomide-resistant gliomas

November 2012

Molecular Cancer Therapeutics 2012, 11:2462.


The development of treatment resistance represents an enormous problem for cancer therapy in general. In the case of malignant gliomas in particular, standard treatment approaches inevitably fail, leaving the patient with no effective further treatment options. This preclinical study demonstrated that perillyl alcohol retained its anticancer effectiveness even in drug-resistant glioma cells. For instance, mice with drug-resistant brain tumors, when treated with intranasal (through the nose) perillyl alcohol, presented with decreased tumor growth and longer survival.

Comments are closed.